The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Endometrial Cancer Treatment Market From 2026 To 2030?
The endometrial cancer treatment market size has demonstrated significant expansion in recent years. It is projected to grow from $32.09 billion in 2025 to $33.85 billion in 2026, showing a compound annual growth rate (CAGR) of 5.5%. The historical growth of this market can be linked to an increasing incidence of endometrial cancer, the limited development of early diagnostic tools, a prevalent preference for conventional chemotherapy, the absence of specific targeted therapies, and low awareness about preventive care.
The endometrial cancer treatment market size is anticipated to experience substantial expansion over the next few years. It is projected to achieve a value of $43.44 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.4%. This growth during the forecast period is largely driven by advancements in genomics and precision medicine, increased adoption of AI-driven diagnostics, the proliferation of targeted and immunotherapy drugs, a rising geriatric population, and improvements in healthcare infrastructure. Key trends expected in the coming period include personalized treatment approaches, minimally invasive surgical techniques, the development of targeted therapies, combination therapy strategies, and enhanced patient monitoring and follow-up.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10735&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Endometrial Cancer Treatment Market?
The increasing occurrence of endometrial cancer is anticipated to drive the expansion of the endometrial cancer treatment market in the future. Endometrial cancer prevalence indicates a rise in diagnosed cases of the disease within a defined group or timeframe. This trend stems from evolving risk factors, enhanced detection and diagnostic techniques, greater public awareness, and an aging demographic. Treatments for endometrial cancer facilitate early diagnosis, offer specific therapies, prevent the disease from returning, and support clinical trials and research aimed at enhancing therapeutic choices. Consequently, with the ongoing increase in endometrial cancer cases and expanding progress in treatment modalities, the endometrial cancer treatment market is projected to expand. For example, in 2023, Cancer.Net, a source for oncologist-verified cancer data, projected that approximately 66,200 individuals in the United States would receive a diagnosis of uterine, or endometrial cancer. Thus, the escalating prevalence of endometrial cancer is fueling the expansion of the endometrial cancer treatment market.
Which Segments Are Included In The Analysis Of The Endometrial Cancer Treatment Market?
The endometrial cancer treatment market covered in this report is segmented –
1) By Type: Adenocarcinoma, Uterine Carcinosarcoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Transitional Carcinoma, Serous Carcinoma, Other Types
2) By Diagnosis Method: Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan, Other Diagnosis Methods
3) By Route Of Administration: Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Adenocarcinoma: Endometrioid Adenocarcinoma, Non-Endometrioid Adenocarcinoma
2) By Uterine Carcinosarcoma: High-Grade Uterine Carcinosarcoma, Low-Grade Uterine Carcinosarcoma
3) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma
4) By Small Cell Carcinoma: Small Cell Neuroendocrine Carcinoma
5) By Transitional Carcinoma: Transitional Cell Carcinoma Of The Uterus
6) By Serous Carcinoma: High-Grade Serous Carcinoma, Low-Grade Serous Carcinoma
7) By Other Types: Mixed Cell Type Carcinomas, Undifferentiated Carcinoma, Other Rare Histological Types
Which Trends Are Impacting The Growth Of The Endometrial Cancer Treatment Market?
Leading companies in the endometrial cancer treatment market are concentrating on developing advanced solutions, such as PD-1 pathway blocking immunotherapy, to boost treatment effectiveness and the durability of patient responses. This type of immunotherapy operates by preventing cancer cells from utilizing the PD-1 mechanism to evade immune detection, thereby enabling immune cells to more precisely identify and attack tumors. This strategy presents a targeted alternative for advanced or recurrent disease where chemotherapy has frequently offered limited long-term benefits. For example, in August 2025, GSK Plc, a biopharmaceutical company based in the UK, launched Jemperli, which incorporates a PD-1 blocking mechanism. This therapy is India’s first approved immunotherapy for the second-line treatment of advanced endometrial cancer that is mismatch repair deficient or microsatellite instability high, and it achieved an objective response rate of 45.5 percent in the GARNET trial. It maintains strong probabilities of a sustained response at 12 and 24 months and features an acceptable safety profile. The introduction of Jemperli addresses a vital unmet need in India, where many patients are diagnosed with advanced disease and require more effective and predictable treatment choices.
Which Key Industry Participants Are Active In The Endometrial Cancer Treatment Market?
Major companies operating in the endometrial cancer treatment market are Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi-Aventis, Teva Pharmaceutical Industries Limited, AstraZeneca plc, Pfizer Inc., Bristol-Myers Squibb Company, Eisai Co. Ltd., AbbVie Inc., Roche Holding AG, Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Bayer AG, Eli Lilly and Company, Varian Medical Systems Inc., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., Stemline Therapeutics Inc.
Read the full endometrial cancer treatment market report here:
https://www.thebusinessresearchcompany.com/report/endometrial-cancer-treatment-global-market-report
What Are The Leading Geographic Regions In The Endometrial Cancer Treatment Market?
North America was the largest region in the endometrial cancer treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global endometrial cancer treatment market report during the forecast period. The regions covered in the endometrial cancer treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Endometrial Cancer Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10735&type=smp
Browse Through More Reports Similar to the Global Endometrial Cancer Treatment Market 2026, By The Business Research Company
Endometrial Cancer Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/endometrial-cancer-treatment-global-market-report
Endometriosis Market Report 2026
https://www.thebusinessresearchcompany.com/report/endometriosis-global-market-report
Gynecological Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/gynecological-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model